VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

RBD-rAAV-SARS-CoV RBD-rAAV-SARS-CoV-02 rMV- SARS-CoV -S/Ssol SARS Subunit Spike Protein Vaccine
Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004678
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: Inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant (Zheng et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004679
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: RBD-rAAV prime/RBD-specific T cell peptide boost (Du et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004711
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: Live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol) (Escriou et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0011486
  • Type: Recombinant vector vaccine
  • Status: Research
  • S protein gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Adjuvant: CpG DNA vaccine adjuvant
  • Vector: Adeno-associated virus (Du et al., 2008).
  • Immunization Route: Subcutaneous injection
Host Response Host Response Host Response Host Response

Mouse Response

  • Vaccination Protocol: Intranasal vaccination with RBD-rAAV (Zheng et al., 2008).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: Mice were challenged with 105 TCID50f SARS-CoV strain GZ50 (Zheng et al., 2008).
  • Efficacy: RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses (Zheng et al., 2008).

Mouse Response

  • Vaccination Protocol: Mice were separated into 4 groups (9 mice per group) and primed with RBD-rAAV [intramuscular (i.m.), 2 × 1011 VP /200 μl)] or RBD-peptides (N50 and N60, 50 μg each) plus CpG ODN (25 μg) [subcutaneous, (s.c.)] or blank AAV, and boosted with RBD-rAAV or RBD-Pep or AAV, respectively (Du et al., 2008).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Forty days post-vaccination, mice were anaesthetized with isoflurane and i.n. inoculated with 50 μl of SARS-CoV strain GZ50 (5 × 105 TCID50) (Du et al., 2008).
  • Efficacy: Compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide (RBD-Pep) boost induced similar levels of Th1 and neutralizing antibody responses that protected the vaccinated mice from subsequent SARS-CoV challenge, but stronger Th2 and CTL responses. No significant immune responses and protective effects were detected in mice vaccinated with RBD-Pep or blank AAV alone (Du et al., 2008).

Mouse Response

  • Vaccination Protocol: Mice were immunized with two intraperitoneal (i.p.) injections at 4-week interval of 105 TCID50 of MV-S or MV-Ssol recombinant viruses (Escriou et al., 2014).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice were inoculated intranasally with 105 pfu of SARS-CoV five weeks after the second immunization (Escriou et al., 2014).
  • Efficacy: Recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV (Escriou et al., 2014).

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were Mice were separated into 4 groups (9 mice per group) and primed with RBD-rAAV [intramuscular (i.m.), 2 × 1011 VP /200 μl)] or RBD-peptides (N50 and N60, 50 μg each) plus CpG ODN (25 μg) [subcutaneous, (s.c.)] or blank AAV, and boosted with RBD-rAAV or RBD-Pep or AAV, respectively (Du et al., 2008).
  • Challenge Protocol: Mice intranasally challenged with SARS-CoV strain GZ50 40 days post-vaccination (Du et al., 2008).
  • Efficacy: SARS-CoV viral load in lung tissues was significantly reduced in mice vaccinated with RBD-Pep. Very low level of viral load was detected in lung tissues of RBD-rAAV prime/RBD-Pep boost group, similar to that in lung tissues of RBD-rAAV prime/RBD-rAAV boost group. Vaccination of RBD-rAAV prime/RBD-peptide boost was able to significantly inhibit SARS-CoV infection (Du et al., 2008).
References References References References
Zheng et al., 2008: Zheng BJ, Du LY, Zhao GY, Lin YP, Sui HY, Chan C, Ma S, Guan Y, Yuen KY. Studies of SARS virus vaccines. Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine. 2008; 14 Suppl 4; 39-43. [PubMed: 18708674].
Du et al., 2008: Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, Zheng BJ. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008; 26(13); 1644-1651. [PubMed: 18289745].
Escriou et al., 2014: Escriou N, Callendret B, Lorin V, Combredet C, Marianneau P, FĂ©vrier M, Tangy F. Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology. 2014; 452-453; 32-41. [PubMed: 24606680].
Du et al., 2008: Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, Zheng BJ. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008; 26(13); 1644-1651. [PubMed: 18289745].